Corporate Presentation
About ZP
In 2024 we are expanding efforts to advance our
pipeline of differentiated obesity assets
ZEAL&
ZEALAND PHARMA
Petrelintide
(amylin analog)
Dapiglutide
(GLP-1R/GLP-2R)
Ph1b 16-week MAD clinical trial
data
Ph2a DREAM clinical trial data1
Ph2b trial initiation
Ph1b 13-week dose-titration
clinical trial data
Survodutide²
(GCGR/GLP-1R)
Boehringer
Ingelheim
Ph2 MASH clinical trial data
Ph3 obesity trial enrollment³
Deliver on rare disease and inflammation pipeline
Regulatory decisions for rare disease assets
Dasiglucagon for CHI
Glepaglutide for SBS
ZP9830 (Kv1.3 lon
Channel Blocker)
First-in-human trial initiation with inflammation assets
ZP10068 (Complement
C3 Inhibitor)4
Notes: 1) DREAM is an investigator-led trial. 2) Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion
rights in the Nordic countries). 3) SYNCHRONIZETM-1 and SYNCHRONIZETM-2. 4) Discovery and development agreement with Alexion, AstraZeneca Rare Disease.
7View entire presentation